Recombinant Human LYPD6 Fc Chimera Protein, CF

When Recombinant Human LYPD6 Fc Chimera (Catalog # 10073-LY) is coated at 2 μg/mL, 100 μL/well, Biotinylated Recombinant Human Frizzled-8 Fc Chimera binds with an ED50 of 2-12 μg/mL.

2 μg/lane of Recombinant Human LYPD6 Fc Chimera was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 58-66 kDa and 120 -130 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LYPD6 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LYPD6 Fc Chimera is immobilized at 2 µg/mL (100 µL/well), Biotinylated Recombinant Human Frizzled-8 Fc Chimera binds with an ED₅₀ of 2-12 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human LYPD6 protein
  

  Human LYPD6 (Ala23-His152) Accession # Q86Y78-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q86Y78-1
• N-terminal Sequence: Ala23
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 41 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 58-66 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LYPD6 Fc Chimera Protein, CF

• LY6/PLAUR domain containing 6
• LYPD6
• UNQ3023/PRO9821

Background

LYPD6 (Ly6/PLAUR domain-containing protein 6) is a member of the Ly6/uPar family of proteins that are either secreted or GPI-anchored to the cell surface. Members of this protein family include immune regulatory molecules like CD59, the urokinase plasminogen activator receptor (uPar) and molecules that regulate cell proliferation, migration and adhesion (1-3). Ly6/uPar proteins are characterized by the presence of variable loop regions which confer the functional diversity of this protein family (4). Human LYPD6 is synthesized as a 171 aa protein that includes a 22 aa signal peptide and a 149 aa LYPD6 chain. Within the main chain region, human LYPD6 shares 95% sequence identity with mouse LYPD6. LYPD6 is an important regulator of embryogenesis in zebrafish through its enhancement of Wnt/ beta -catenin signaling (5). It is widely expressed in human tissues with higher expression level in the brain and the heart (5-7). Studies have shown LYPD6 can interact with Frizzled-8 and LRP6, and it is required for Wnt-8-mediated mesoderm and neuroectoderm patterning (5). Also, it has been shown LYPD6 can interact with several nicotinic acetylcholine receptors (nAChRs) in the human brain (7). Soluble recombinant LYPD-6 can inhibit nicotine-induced phosphorylation of ERK in PC12 cells and attenuate nicotine-induced hippocampal inward currents in rat brain slices (7).

1. Kong, B.H. and J.H. Park (2012) BMB Rep. 45:595.
2. Bamezai, A. (2004) Arch. Immunol. Ther. Exp. (Warsz.) 52:255.
3. Gumley, T.P. et al. (1995) Immunol. Cell. Biol. 73:277.
4. Vasilyeva, N.A. et al. (2017) Biochemistry (Mosc.) 82:1702.
5. Özhan, G. et al. (2013) Dev Cell. 26(4):331.
6. Zhang, Y. et al. (2010) Mol Biol Rep 37:2055.
7. Arvaniti, M. et al. (2016) J. Neurochem. 138:806.

Bioinformatics

• Uniprot:
  • Q86Y78-1()